Topics

Qiagen said today it has launched its QIAstat-Dx syndromic testing system along with the multiplex QIAstat-Dx respiratory panel after receiving FDA 510(k) clearances. QIAstat-Dx (formerly...

Artificial intelligence (AI) is gaining a foothold in the discovery and development of drugs and diagnostics—but its use in both will remain limited unless companies surmount hurdles to the technology in the next few years, a panel of industry executives agreed.

Sponsor: ThermoFisher

MGI, the sequencing instruments subsidiary of BGI Group, said today it has raised more than $200 million in its first financing round—the largest amount...

Natera’s Signatera test has shown potential in a newly-published survey for guiding treatment decisions after surgery by identifying colorectal cancer recurrence at an average...

RenalytixAI will assess its lead product, the AI-enabled kidney disease diagnostic KidneyIntelX, in more than 3,500 patients with Type II diabetes through a collaboration...

Steven Kafka, Ph.D., the former president and chief operating officer of Foundation Medicine who left the company last year, has joined with former colleagues...

PrediLife said it will carry out genetic analyses in connection with its MammoRisk personalized breast cancer screening test through a partnership with the Institut...

MDxHealth has presented positive data designed to demonstrate the accuracy and decision-making value of its two prostate cancer tests, ConfirmMDx and SelectMDx. The molecular diagnostics...

HTG Molecular Diagnostics said today it has expanded a 4½-year-old agreement with Illumina allowing for development of in-vitro diagnostic (IVD) test kits for use...